JPH0748991B2 - Tube feeding composition - Google Patents
Tube feeding compositionInfo
- Publication number
- JPH0748991B2 JPH0748991B2 JP59179867A JP17986784A JPH0748991B2 JP H0748991 B2 JPH0748991 B2 JP H0748991B2 JP 59179867 A JP59179867 A JP 59179867A JP 17986784 A JP17986784 A JP 17986784A JP H0748991 B2 JPH0748991 B2 JP H0748991B2
- Authority
- JP
- Japan
- Prior art keywords
- emulsion
- lipid
- tube
- acid
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Seeds, Soups, And Other Foods (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
【発明の詳細な説明】 〔産業上の利用分野〕 この発明は手術前、手術後の患者等に対する栄養補給に
使用される経管栄養組成物に関するものである。DETAILED DESCRIPTION OF THE INVENTION [Industrial application] The present invention relates to a tube feeding composition used for nutritional supplementation to patients before and after surgery.
〔従来の技術〕 中心静脈栄養法や経腸栄養法などの経管栄養法は外科、
特に消化器外科の補助療法としての輸液、栄養の面で重
要な位置を占めている。特に経管栄養法の一般的な方法
として知られているチューブ栄養（tube feeding）は鼻
腔、食道を通じてチューブを挿入し胃内または空腸内に
とどめ流動性栄養物を与える方法である。また腸管外栄
養として、消化器以外の場所からの栄養補給法には、静
脈内注射、皮下注射、筋肉注射および腹腔内注射などが
ある。[Prior Art] Tube feeding such as central parenteral feeding or enteral feeding is surgery,
In particular, it occupies an important position in terms of infusion and nutrition as an adjunctive therapy for digestive surgery. In particular, tube feeding, which is known as a general method of tube feeding, is a method of inserting a tube through the nasal cavity and esophagus and retaining it in the stomach or jejunum to give a fluid nutrition. As parenteral nutrition, methods of nutritional supplementation from locations other than the digestive system include intravenous injection, subcutaneous injection, intramuscular injection, and intraperitoneal injection.
S.J.Dudrickは1968年に高カロリー輸液の臨床成功例
を、また、J.E.Fischerは肝不全時の肝性昏睡眼の覚醒
効果にFischer液が有効であること等発表した。これら
の成功により、我国においても小児外科や一般外科にこ
れらの方法が取入れられた。この高カロリー輸液の成功
をきっかけに、経腸的高カロリー栄養と呼ばれる成分栄
養法が発達した。SJ Dudrick announced the clinical success case of high calorie infusion in 1968, and JE Fischer announced that Fischer's solution is effective for the awakening effect of hepatic coma during liver failure. Due to these successes, these methods have been incorporated into pediatric surgery and general surgery in Japan. With the success of this high-calorie infusion, a component nutrition method called enteral high-calorie nutrition was developed.
チューブの種類には単管と二重管があるが、単管チュー
ブは昏睡あるいは嗜眠状態、開口不能、嚥下障害等に適
している。チューブ栄養に適する食事の条件は、流動食
であることが必要であり、味は不問であるが、消化ずみ
の状態、すなわち消化態栄養剤が最良である。各栄養素
の配合は糖質の60〜80％、たん白質20〜30％、脂質５〜
10％が良い、水分は１日2000〜3000mlは注入すべきであ
る。There are two types of tubes, single tube and double tube. Single tube is suitable for coma or drowsiness, dysphagia, dysphagia, etc. The dietary conditions suitable for tube nutrition need to be liquid diets, taste is irrelevant, but digested, ie digested nutrients are best. The composition of each nutrient is 60 to 80% of sugar, 20 to 30% of protein, and 5 to lipid.
10% is good, 2000-3000ml of water should be infused daily.
しかしながら高カロリー輸液の研究の進歩により、生体
の基体的な代謝を営むのに最低必要な割合として、全投
与カロリー中に占める各基質の量は、糖質20％、アミノ
酸10％、脂質10％であり、残り60％は何でも良いという
考えも出てきた。したがってアメリカ式の糖質の多い場
合は、糖質80％、アミノ酸10％、脂質10％となり、この
時は高浸透圧のため中心静脈への輸液が必要であり、ヨ
ーロッパ式の脂質の多い時は、アミノ酸10％、糖質20
％、脂質70％となり、抹消静脈を用いても管理可能とい
うことがわかってきた。However, due to the progress of research on high calorie infusion, the amount of each substrate in the total calories administered is 20% of sugar, 10% of amino acid, and 10% of lipid as the minimum necessary ratio to carry out basic metabolism of the living body. And there is the idea that the remaining 60% can be anything. Therefore, in the case of American-style high-sugar, 80% of sugar, 10% amino acid and 10% of lipid are required. At this time, it is necessary to infuse into central vein due to high osmotic pressure. Is 10% amino acids, 20 carbohydrates
%, Lipids became 70%, and it has become clear that management is possible even using peripheral veins.
各基質についての研究も進み、糖質については代謝の面
より、炭酸ガスまでの代謝速度はグルコース、フルクト
ース、マルトース、ソルビトール、キシリトールの順で
あることが明らかになった。アミノ酸に関しても従来の
アミノ酸輸液製剤をさらに改善し、チロシンやフエニル
アラニンなどの芳香族アミノ酸とロイシン、イソロイシ
ン、バリンなどの分枝鎖アミノ酸の芳香族アミノ酸に対
するモル比が肝硬変患者の累積生存率が高いことなども
報告されている。Studies on each substrate have also progressed, and it has been clarified that the rate of metabolism of carbon dioxide up to carbon dioxide is glucose, fructose, maltose, sorbitol, and xylitol in that order from the viewpoint of metabolism. Regarding amino acids, the conventional amino acid infusion preparations have been further improved, and the molar ratio of aromatic amino acids such as tyrosine and phenylalanine and branched chain amino acids such as leucine, isoleucine, and valine to aromatic amino acids has been shown to improve the cumulative survival rate of patients with cirrhosis. It is also reported to be expensive.
脂質に関しては総熱量中の脂質量が50〜60％まで検討さ
れ、脂質組成については必須脂肪酸としてのリノール酸
の投与量を成人では総熱量の５％が最少量として確認さ
れたのみで、脂質の組成について具体的な検討はされて
いない。Regarding lipids, the amount of lipids in the total calorific value was examined up to 50-60%, and regarding the lipid composition, the dose of linoleic acid as an essential fatty acid was confirmed to be 5% of the total caloric value as the minimum amount in adults. No specific study has been made on the composition of the.
このような従来の経管栄養法による高カロリー輸液は、
脂質に関しては栄養維持が目的であり、病態改善は効果
がないという問題があった。High calorie infusion by such conventional tube feeding method,
Regarding lipids, the purpose was to maintain nutrition, and there was a problem that improvement of pathological conditions was ineffective.
この発明は上記問題点を解決するためのもので、脂質と
して病態改善効果のある特定の脂質を配合してO/W型エ
マルジョンを形成することにより、栄養維持に加えて、
治療効果が得られ、かつ酸化安定性に優れた経管栄養組
成物を提案する。This invention is for solving the above-mentioned problems, by forming a O / W type emulsion by mixing a specific lipid having a pathological condition improving effect as a lipid, in addition to nutritional maintenance,
A tube feeding composition having a therapeutic effect and excellent in oxidative stability is proposed.
この発明は、糖質、たん白質またはその分解物、脂質、
ミネラルおよびビタミンを主成分とする経管栄養組成物
において、脂質としてリノール酸およびリノレン酸から
選ばれる１種以上の不飽和脂肪酸を５重量％以上含有す
る第１の脂質と、エイコサペンタエン酸およびドコサヘ
キサエン酸から選ばれる１種以上の高度不飽和脂肪酸を
５重量％以上含有する第２の脂質とを、合計量で全固形
分中５〜30重量％配合し、O/W型エマルジョンを形成し
たことを特徴とする経管栄養組成物である。This invention is a saccharide, a protein or a degradation product thereof, a lipid,
In a tube-feed nutrition composition containing minerals and vitamins as main components, a first lipid containing 5% by weight or more of one or more unsaturated fatty acids selected from linoleic acid and linolenic acid as lipids, and eicosapentaenoic acid and docosahexaene Forming an O / W emulsion by blending a total amount of 5 to 30% by weight of the total solid content with a second lipid containing 5% by weight or more of one or more highly unsaturated fatty acids selected from acids. A tube-feeding nutritional composition.
本発明の経管栄養組成物は人体に必要な栄養分を供給す
るために、糖質、たん白質またはその分解物、ミネラル
およびビタミンを主成分とする。経管栄養組成物は経口
以外にて栄養成分を補給するため、水溶液中に各成分を
溶解してチューブに輸送されるので、糖質、たん白質ま
たはその分解物、脂質等が使用され、O/W型エマルジョ
ンとされる。The tube feeding composition of the present invention contains sugars, proteins or their decomposition products, minerals and vitamins as main components in order to supply the human body with necessary nutrients. Since the tube feeding composition supplements nutritional components other than oral, since each component is dissolved in an aqueous solution and transported to a tube, a sugar, a protein or a decomposed product thereof, a lipid, etc. are used. / W emulsion.
糖質としては、胃に注入する場合には一般の粉末製剤に
使用されるデキストリン（デキストロース・イキューバ
レント24程度）、ラクトース、シュークロース等が使用
できるが、その他の場合には消化態栄養として、グルコ
ース、フラクトース、マルトース等を使用する。製品を
粉末化する場合、噴霧乾燥機の槽内温度が80℃近辺にな
るように送風温度を120〜140℃にコントロールすると、
フラクトース、マルトース等は乾燥機塔内壁に粉末が長
時間堆積されてカラメル化または一部熔融褐変化するた
め、取扱に注意を要するので、グルコースが最も好まし
い。As sugars, when injecting into the stomach, dextrin (dextrose, icuvalent about 24), lactose, sucrose, etc. used in general powder formulations can be used, but in other cases, as digestive nutrition , Glucose, fructose, maltose, etc. are used. When powdering the product, control the blast temperature to 120-140 ° C so that the temperature inside the spray dryer is around 80 ° C.
Glucose is most preferable because fructose, maltose and the like are powdered on the inner wall of the dryer for a long time and caramelized or partially melted and browned.
たん白質としては、胃に注意する場合はカゼイン、カゼ
インナトリウム、乳たん白質等が使用できるが、他の場
合はたん白質分解物である消化態のアミノ酸を使用す
る。このようなアミノ酸としては、基準となるべきヒト
のアミノ酸要求割合について、1973年にFAO/WHO合同特
別専門委員会がヒトのたん白質所要量を答申した組成物
が望ましい。この組成物はFAO/WHO型アミノ酸輸液製剤
として市販されているものが使用可能である。ミネラル
およびビタミンについても、経管栄養組成物に施用され
ている組成のものが使用でき、ビタミンについては市販
の総合ビタミン剤が使用可能である。As the protein, casein, casein sodium, milk protein and the like can be used when the stomach is taken care of, but in other cases, digested amino acids which are protein degradation products are used. As such an amino acid, it is desirable to use a composition in which the FAO / WHO Joint Special Task Force reported the required amount of human protein in 1973, regarding the human amino acid requirement ratio to be the standard. As this composition, a commercially available FAO / WHO type amino acid infusion preparation can be used. Regarding the minerals and vitamins, those having the composition applied to the tube feeding composition can be used, and as the vitamins, commercially available multivitamin preparations can be used.
脂質は従来ノリール酸を含有する大豆油、サフラワー
油、あるいはリノレン酸を含有するマツヨイグサ種子油
等が利用されてきたが、本発明では単なるカロリー補給
より一歩進め、治療効果のある脂質として従来から用い
られている第１の脂質のほかに、高度不飽和脂肪酸を含
有する第２の脂質を配合する。第１の脂質はノリール酸
およびリノレン酸から選ばれる不飽和脂肪酸を５重量％
以上含有する脂質であり、リノレン酸、γ−リノレン酸
（GLA）、ジホモ−γ−リノレン酸（DGLA）等が含まれ
る。第２の脂質はエイコサペンタエン酸（EPA）および
ドコサヘキサエン酸（DHA）から選ばれる高度不飽和脂
肪酸を５重量％以上含有する脂質である。Lipids have conventionally been used soybean oil containing norilic acid, safflower oil, or evening primrose seed oil containing linolenic acid, etc., but in the present invention, it is one step further than simple calorie supplementation, and it has been conventionally used as a therapeutic lipid. In addition to the first lipid used, a second lipid containing polyunsaturated fatty acids is compounded. The first lipid is 5% by weight of an unsaturated fatty acid selected from norilic acid and linolenic acid.
The lipids contained above include linolenic acid, γ-linolenic acid (GLA), dihomo-γ-linolenic acid (DGLA) and the like. The second lipid is a lipid containing 5 wt% or more of a highly unsaturated fatty acid selected from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
EPAおよびDHAは食用魚油等に含まれ、心筋梗塞、血栓性
疾患などの予防や治療に有効であり、また血清コレステ
ロールを低下させる作用を有する。GLAはマツヨイグサ
種子油等に含まれ、老化によるリノール酸からGLAへの
変換能力低下やGLAの代謝産物、特に１型プロスタグラ
ンジンＥ（PGE）をつくる能力の喪失に対する改善作用
を有する。DGLAは哺乳類の生体に含まれ、PGEの直接の
前駆体であり、心脈管系、消化器系、内分泌系において
血管症の改善などの作用を有する。EPA and DHA are contained in edible fish oil and the like, and are effective in the prevention and treatment of myocardial infarction, thrombotic diseases and the like, and have the action of lowering serum cholesterol. GLA is contained in evening primrose seed oil and the like, and has an action of improving the ability to convert linoleic acid to GLA due to aging and the loss of the ability to produce GLA metabolites, especially prostaglandin E type 1 (PGE). DGLA is contained in the living body of mammals and is a direct precursor of PGE, and has actions such as improvement of vascular disease in the cardiovascular system, digestive system and endocrine system.
上記の脂質原料はいずれも生体中にてプロスタグランジ
ン（PG）前駆体となる脂肪酸を豊富に有する。このうち
第２の脂質に含まれるEPAおよびDHAはω−３系の血栓溶
解作用を有する物質を生成するのに対し、第１の脂質に
含まれるノリール酸やGLA等はω−６系PG前駆体とな
り、血液凝固作用を有する物質を生成する。このためこ
れらを併用すると、拮抗作用により相乗効果が得られ
る。Each of the above-mentioned lipid raw materials has abundant fatty acids that serve as prostaglandin (PG) precursors in the living body. Of these, EPA and DHA contained in the second lipid produce ω-3 type substances having a thrombolytic action, whereas norilic acid and GLA contained in the first lipid have ω-6 type PG precursors. It becomes the body and produces substances that have a blood coagulation effect. Therefore, when these are used in combination, a synergistic effect is obtained by an antagonistic action.
ところで、糖質、アミノ酸、電解質等は水溶性であるか
らチューブ輸送の溶液として問題はないが、単位当り、
高カロリーの熱量を補給するためには、脂質添加が必要
となる。この場合、治療、予防効果を付与するために
は、EPAおよびDHAから選ばれる高度不飽和脂肪酸を、脂
質中に５重量％以上含有させる必要がある。By the way, since sugars, amino acids, electrolytes, etc. are water-soluble, there is no problem as a solution for tube transportation, but
Lipid addition is required to replenish the high calorie heat. In this case, in order to impart a therapeutic or preventive effect, it is necessary to make the lipid contain a polyunsaturated fatty acid selected from EPA and DHA in an amount of 5% by weight or more.
EPAおよびDHAはGLAよりも二重結合が２〜３個多いた
め、100〜1000倍程度速く酸化されやすい。また経管栄
養組成物には、酸化を促進するミネラルが配合されるた
め、経管栄養組成物中にEPA、DHAを単純に配合するだけ
では、酸化による過酸化物の生成を防止できない。Since EPA and DHA have 2 to 3 more double bonds than GLA, they are easily oxidized about 100 to 1000 times faster. In addition, since the tube-feeding nutritional composition contains a mineral that promotes oxidation, it is not possible to prevent the generation of peroxide due to oxidation simply by adding EPA and DHA to the tube-feeding nutritional composition.
EPA、DHAを含む脂質を配合して、酸化安定性の高い経管
栄養組成物を得るためには、脂肪乳剤すなわちO/W型エ
マルジョンを形成し、その安定性を高くする必要があ
る。このためには第１および第２の脂質の合計配合割合
を栄養剤全固形物中５〜30重量％とし、蔗糖脂肪酸エス
テル、脂肪酸モノグリセリドまたはその有機酸エステ
ル、プロピレングリコール脂肪酸エステル、レシチン等
の乳化剤を加えて乳化することにより、O/W型エマルジ
ョンを形成し、油滴の周囲の水溶性成分で脂質が覆われ
た状態とする。In order to obtain a tube-feeding nutrition composition having a high oxidative stability by incorporating a lipid containing EPA and DHA, it is necessary to form a fat emulsion, that is, an O / W type emulsion, and increase its stability. For this purpose, the total content of the first and second lipids is 5 to 30% by weight based on the total solid content of the nutrient, and the emulsifiers such as sucrose fatty acid ester, fatty acid monoglyceride or its organic acid ester, propylene glycol fatty acid ester, and lecithin are used. By adding and emulsifying, an O / W type emulsion is formed, and the lipid is covered with the water-soluble components around the oil droplets.
これにより脂質量に関係なく安定なO/W型エマルジョン
が調整できるため、各種の脂質を添加し、経管栄養組成
物を液状で輸液することができる。O/W型エマルジョン
の状態では、EPA、DHA等の高度不飽和脂肪酸を含む脂質
は水溶性成分により覆われているため、酸化安定性が増
すとともに、これらの脂質に伴う魚臭も消去される。ま
た目的の脂質を水溶性成分でコーティングできるので、
経管栄養組成物を粉末や顆粒で保存し、使用に際し可溶
化すれば任意に使用することができる。As a result, a stable O / W emulsion can be prepared irrespective of the amount of lipid, so that various types of lipids can be added and the tube feeding composition can be infused in liquid form. In the state of O / W emulsion, lipids containing highly unsaturated fatty acids such as EPA and DHA are covered with water-soluble components, which increases oxidative stability and eliminates fish odor associated with these lipids. . Also, since the target lipid can be coated with a water-soluble component,
The tube-feeding nutritional composition can be arbitrarily used as long as it is stored as a powder or granules and solubilized at the time of use.
本発明の経管栄養組成物は上記成分以外に、酸化防止剤
等の他の成分を配合してもよい。酸化防止剤としてトコ
フェロールを配合すると、ビタミンＥとしての作用も兼
ねさせることができる。In addition to the above components, the tube feeding composition of the present invention may contain other components such as an antioxidant. When tocopherol is added as an antioxidant, it can also function as vitamin E.
本発明の経管栄養組成物は、水溶性成分および乳化剤を
水に溶解して水溶液とし、油溶性成分を脂質に溶解した
混合液を上記水溶液にゆっくり滴下しながら攪拌して予
備乳化させ、この予備乳化液をホモジナイザーにより乳
化してO/W型エマルジョンとする。このエマルジョンは
殺菌後そのままで経管栄養組成物の製品とすることもで
きるが、必要により噴霧乾燥して粉末化することもでき
る。The tube feeding composition of the present invention comprises a water-soluble component and an emulsifier dissolved in water to form an aqueous solution, and a mixed solution prepared by dissolving an oil-soluble component in a lipid is preliminarily emulsified by slowly adding dropwise to the aqueous solution while stirring. The preliminary emulsion is emulsified with a homogenizer to obtain an O / W type emulsion. This emulsion can be used as a product of tube feeding composition as it is after sterilization, but can also be spray-dried and powdered if necessary.
こうして得られる経管栄養組成物は、製品がエマルジョ
ンの場合はそのまま、または希釈して、また粉末の場合
は水を添加してエマルジョンとして、経管により手術前
後の患者の胃、腸、静脈等に供給する。エマルジョンは
適度の粘度を有するためチューブ中を滞りなく流下し、
安定して供給される。そして患者がこれを摂取すること
により、栄養維持とともに、高度不飽和脂肪酸の薬理作
用により病態改善効果がある。The tube-feeding composition thus obtained is used as it is when the product is an emulsion, or when it is diluted, or when it is a powder, it is added as water to form an emulsion. Supply to. Since the emulsion has an appropriate viscosity, it will flow down the tube without interruption,
Stable supply. Then, when the patient ingests this, it has the effect of improving the condition by maintaining the nutrition and the pharmacological action of the polyunsaturated fatty acid.
本発明によれば、経管栄養組成物の脂質として、リノー
ル酸、リノレン酸のようなω−６系不飽和脂肪酸を５重
量％以上含む第１の脂質と、EPA、DHAのようなω−３系
高度不飽和脂肪酸を５重量％以上含む第２の脂質とを、
合計量で５〜30重量％配合してO/Wエマルジョンとした
ので、拮抗作用により相乗効果が得られ、栄養維持とと
もに心筋梗塞、血栓性疾患などの予防や治療に有効であ
り、しかも酸化安定性が高く、EPA、DHAに起因する魚臭
も消去され、扱いやすい経管栄養組成物が得られる効果
がある。According to the present invention, as the lipid of the tube feeding composition, the first lipid containing 5 wt% or more of ω-6 unsaturated fatty acid such as linoleic acid and linolenic acid, and ω-such as EPA and DHA. A second lipid containing 5% by weight or more of 3 type highly unsaturated fatty acid,
Since the total amount is 5 to 30% by weight to make an O / W emulsion, a synergistic effect can be obtained by an antagonistic effect, which is effective in preventing and treating myocardial infarction, thrombotic diseases, etc. while maintaining nutrition, and is stable in oxidation. It is highly effective and eliminates the fish odor caused by EPA and DHA, and provides an easy-to-handle tube feeding composition.
以下、本発明の実施例について説明する。各例中、部は
重量部を、％は重量％を示す。Examples of the present invention will be described below. In each example, “part” means “part by weight” and “%” means “% by weight”.
比較例１ 水100部を80℃に加温し、攪拌しながら蔗糖脂肪酸エス
テル（HLB15）を１部、表１のアミノ酸製剤を20部、表
２のビタミン製剤を所定量、表３のミネラル製剤を所定
量、およびグルコースを60部の順序で添加し、これらの
水溶性成分を完全に溶解させるため、80℃に保持しなが
ら30分間攪拌した。Comparative Example 1 100 parts of water was heated to 80 ° C., 1 part of sucrose fatty acid ester (HLB15) while stirring, 20 parts of amino acid preparation of Table 1, predetermined amount of vitamin preparation of Table 2, mineral preparation of Table 3 Was added in the order of 60 parts and glucose, and in order to completely dissolve these water-soluble components, the mixture was stirred for 30 minutes while maintaining it at 80 ° C.
一方、マツヨイグサ種子油18.5部（γ−リノレン酸８％
含有）に、卵黄レシチンを0.5部、およびα−トコフェ
ロールを種子油100g当り100I.U.溶解し、80℃に加温し
た。この混合液を上記水溶液にゆっくり滴下しながら80
℃で攪拌を続け、O/W型エマルジョンの予備乳化を30分
間行った。そしてこの予備乳化液を乳化槽より高圧噴射
式ホモジナイザーにポンピングし、第一次圧力150kg/cm
2、第二次圧力100kg/cm2の２段乳化を行った。 On the other hand, 18.5 parts of evening primrose seed oil (γ-linolenic acid 8%
0.5 parts of egg yolk lecithin and α-tocopherol were dissolved in 100 I.U. per 100 g of seed oil, and the mixture was heated to 80 ° C. While slowly adding this mixed solution to the above aqueous solution,
The stirring was continued at 0 ° C., and the O / W type emulsion was pre-emulsified for 30 minutes. Then, pump this pre-emulsion from the emulsification tank to a high pressure injection type homogenizer, and the primary pressure is 150 kg / cm.
2. Second-stage emulsification with a secondary pressure of 100 kg / cm 2 was performed.
得られた乳剤は室温で20cP以下であって非常に粘性が低
く、ろ紙でろ過しても全く残渣がなかった。この乳剤を
共栓シリンダーに入れて40℃で24時間放置したが、脂肪
層および水層の分離はなく、粘性がわずかに上昇したよ
うに観察された。乳剤は独特の臭味を呈すが、刺激臭や
極度な味はなかった。そして直径2mmのテフロンチュー
ブ中を落下させたところ、この乳剤は滞りなく流下し
た。The obtained emulsion had a viscosity of 20 cP or less at room temperature and had a very low viscosity, and no residue was found when filtered through a filter paper. The emulsion was placed in a stoppered cylinder and allowed to stand at 40 ° C. for 24 hours, but there was no separation of the fat layer and the water layer, and it was observed that the viscosity increased slightly. The emulsion had a peculiar odor, but no pungent odor or extreme taste. When it was dropped in a Teflon tube having a diameter of 2 mm, this emulsion flowed down smoothly.
実施例１ 水100部を80℃に加温し、攪拌しながら蔗糖脂肪酸エス
テル（HLB15）を１部、表１のアミノ酸製剤を20部、表
２のビタミン製剤を所定量、表３のミネラル製剤を所定
量、グルコースを70部の順序で添加し、これらの水溶性
成分を完全に溶解させるため、80℃に保持しながら30分
間攪拌した。Example 1 100 parts of water was heated to 80 ° C., 1 part of sucrose fatty acid ester (HLB15) while stirring, 20 parts of amino acid preparation of Table 1, predetermined amount of vitamin preparation of Table 2, mineral preparation of Table 3 A predetermined amount of glucose was added in the order of 70 parts, and in order to completely dissolve these water-soluble components, the mixture was stirred for 30 minutes while maintaining it at 80 ° C.
一方、濃縮魚油（EPA18重量％、DHA7重量％含有）7.5部
に、サフラワー油（リノール酸76.5重量％含有）を1.0
部、卵黄レシチンを0.5部、およびα−トコフェロール
を脂肪100g当り100I.U.添加した。この脂肪は非常に加
熱安定性が悪いので、これらの長時間加熱をさけるた
め、卵黄レシチンとα−トコフェロールは40℃以下、窒
素気流下で溶解したものを全体に分散させて窒素バブリ
ングした。On the other hand, 7.5 parts of concentrated fish oil (containing 18% by weight of EPA and 7% by weight of DHA) and 1.0 part of safflower oil (containing 76.5% by weight of linoleic acid)
Parts, 0.5 parts egg yolk lecithin, and 100 I.U. of α-tocopherol per 100 g of fat. Since this fat has very poor heat stability, egg yolk lecithin and α-tocopherol were dissolved in a nitrogen stream at 40 ° C. or less and dispersed in the whole, and nitrogen bubbling was performed in order to avoid heating for a long time.
次に予備乳化槽に前記水溶性成分の溶液を入れて80℃に
保温攪拌しながら脂肪組成物をゆっくりと滴下し、O/W
型エマルジョンの予備乳化30分間行った。この予備乳化
液を乳化槽より高圧噴射式ホモジナイザーにポンピング
し、第一次圧力150kg/cm2、第二次圧力100kg/cm2の２段
乳化を行った。Next, put the solution of the water-soluble component in the preliminary emulsification tank, slowly add dropwise the fat composition while stirring while maintaining the temperature at 80 ° C., and add O / W.
Pre-emulsification of the type emulsion was carried out for 30 minutes. This pre-emulsion was pumped from the emulsification tank to a high-pressure jet homogenizer to perform a two-stage emulsification with a primary pressure of 150 kg / cm 2 and a secondary pressure of 100 kg / cm 2 .
次いで乳化液を噴霧乾燥機のチャージタンクへ送って、
アトマイザー入口へ供給し、乳化液を噴霧乾燥機中に微
細粒子として噴出させるため、アトマイザーの回転数8,
000から10,000r.p.mにした。噴霧乾燥機は槽内温度が75
〜80℃になるように熱源をコントロールした。この時の
送風温度は125〜130℃で、排風温度は85〜90℃であっ
た。噴霧乾燥機内の塔内壁に粉末が長時間堆積されない
ように塔壁に常時振動を与え、エアースローで運搬され
た粉体は、ポリエチレン製の袋に窒素シールしながら充
填密封し、７日間５℃の保冷庫に保存した。Then send the emulsion to the charge tank of the spray dryer,
The atomizer rotation speed is 8, because the emulsion liquid is supplied to the atomizer inlet and ejected as fine particles into the spray dryer.
It was changed from 000 to 10,000 rpm. The temperature inside the spray dryer is 75
The heat source was controlled so that the temperature was -80 ° C. At this time, the blast temperature was 125-130 ℃, and the exhaust temperature was 85-90 ℃. To prevent powder from accumulating on the inner wall of the spray drier for a long time, the tower wall is constantly vibrated, and the powder conveyed by air throw is filled and sealed in a polyethylene bag with nitrogen sealing for 7 days at 5 ° C. It was stored in a refrigerator.
得られた粉末は、タッピング比容積2.3ml/g、淡黄色で
ケーキング性がなく、低い安息角で落下し、篩別状態も
良好であった。また油のしみ出しがなく、独特のアミノ
酸臭を有するが、水への溶解性が非常に良好であった。The obtained powder had a tapping specific volume of 2.3 ml / g, was pale yellow, had no caking property, fell at a low repose angle, and had a good sieving state. In addition, it did not exude oil and had a unique amino acid odor, but its solubility in water was very good.
この粉末を厚さ９μｍのアルミ箔フィルムに窒素シール
しながらシールを閉じた。そして10℃の冷蔵庫に３カ月
保存後、包装材料を開封し、試験粉体の色調、臭、性状
を判断したが、製造直後の性状と変化はなく、粉体に含
まれる油分を抽出してその過酸化物価を測定したとこ
ろ、4.3meq/kgと低く、問題はなかった。この粉末を固
形分濃度で50％（油脂分は15％）溶液になるように水に
溶解して、乳剤を調整した。得られた乳剤は室温で20cP
以下と非常に粘性が低く、ろ紙でろ過しても全く残渣が
なかった。この乳剤を共栓シリンダーに入れて40℃で24
時間放置したが、脂肪層および水層の分離はなく粘性が
わずかに上昇したように観察された。乳剤は独特の臭味
を呈するが、刺激臭や極度な味はなかった。そして直径
2mmのテフロンチューブ中を落下させたが、この乳剤は
滞りなく流下した。The seal was closed while nitrogen-sealing this powder on an aluminum foil film having a thickness of 9 μm. Then, after storing the packaging material in a refrigerator at 10 ° C for 3 months, the packaging material was opened and the color tone, odor, and properties of the test powder were judged, but there was no change from the properties immediately after production, and the oil content contained in the powder was extracted. When the peroxide value was measured, it was as low as 4.3 meq / kg, and there was no problem. This powder was dissolved in water so as to form a 50% solids (15% fat and oil) solution, and an emulsion was prepared. The resulting emulsion is 20 cP at room temperature
The viscosity was very low as follows, and there was no residue even after filtration with filter paper. Place this emulsion in a stoppered cylinder at 40 ° C for 24 hours.
After being left for a period of time, it was observed that the viscosity was slightly increased without separation of the fat layer and the water layer. The emulsion had a peculiar odor, but no pungent odor or extreme taste. And the diameter
Although it was dropped in a 2 mm Teflon tube, the emulsion flowed down smoothly.
実施例２ 水100部を80℃に加温し、攪拌しながらステアリン酸モ
ノグリセリドのコハク酸エステル（HLB15）を１部、カ
ゼインナトリウムを10部、全卵分解物を５部、表２のビ
タミン製剤を所定量、表３のミネラル製剤を所定量、グ
ルコースを70部の順序で添加して溶解させた。Example 2 100 parts of water is heated to 80 ° C., 1 part of succinic acid ester of stearic acid monoglyceride (HLB15), 10 parts of sodium caseinate, 5 parts of whole egg hydrolyzate, and vitamin preparations shown in Table 2 while stirring. Was added in a predetermined amount, a predetermined amount of the mineral preparation shown in Table 3 and glucose in the order of 70 parts to dissolve them.
一方、マツヨイグサ種子油９部（γ−リノレン酸８％含
有）にコーン油（DGLA2％配合品）を５部、濃縮魚油
（実施例１と同じもの）４部、卵黄レシチンを0.5部、
およびα−トコフェロールを種子油100g当り100I.U.溶
解し、比較例１と同様にしてO/W型エマルジョンを得
た。On the other hand, 5 parts of corn oil (containing 2% of DGLA) in 5 parts of evening primrose seed oil (containing 8% of γ-linolenic acid), 4 parts of concentrated fish oil (the same as in Example 1), 0.5 part of egg yolk lecithin,
And 100 I.U. of α-tocopherol were dissolved in 100 g of seed oil, and an O / W type emulsion was obtained in the same manner as in Comparative Example 1.
得られた乳剤は室温で20cP以下と非常に粘性が低く、ろ
紙でろ過しても全く残渣がなかった。この乳剤を共栓シ
リンダーに入れて40℃で24時間放置したが、脂肪層およ
び水層の分離はなく、粘性がわずかに上昇したように観
察された。乳剤は独特の臭味を呈するが、刺激臭や極度
な味はなかった。そして直径2mmのテフロンチューブ中
を落下させたが、この乳剤は滞りなく流下した。The obtained emulsion had a very low viscosity of 20 cP or less at room temperature and had no residue even when filtered through filter paper. The emulsion was placed in a stoppered cylinder and allowed to stand at 40 ° C. for 24 hours, but there was no separation of the fat layer and the water layer, and it was observed that the viscosity increased slightly. The emulsion had a peculiar odor, but no pungent odor or extreme taste. Then, it was dropped in a Teflon tube having a diameter of 2 mm, but this emulsion flowed down smoothly.
前記実施例１、２および比較例１の乳剤を、脳梗塞等で
植物状態になった患者それぞれ10例に対して経管投与を
行った。投与開始後８週間後に、それぞれの患者の血栓
溶解性について測定を行った結果を表４に示す。The emulsions of Examples 1 and 2 and Comparative Example 1 were administered by gavage to 10 patients each having a vegetative state due to cerebral infarction or the like. Table 4 shows the results obtained by measuring the thrombolytic properties of each patient 8 weeks after the start of administration.
表４のｔ−PA（血栓を溶解する）、PAI−Ｉ（血栓を起
き易くする）の数値より、実施例１、２のものはｔ−PA
が著しく増加し、PAI−Ｉが著しく低下し、血栓溶解性
効果が認められた。それと比較して比較例１のものはそ
れぞれの数値に変化がなく、血栓溶解性効果が認められ
なかった。 From the values of t-PA (dissolving thrombus) and PAI-I (making thrombus easy to occur) in Table 4, the values of Examples 1 and 2 are t-PA.
Markedly increased, PAI-I significantly decreased, and a thrombolytic effect was observed. In comparison with that, in Comparative Example 1, the respective numerical values did not change, and the thrombolytic effect was not recognized.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 ＦＩ 技術表示箇所 // Ａ６１Ｋ 31/20 ＡＣＢ 9454−4Ｃ (56)参考文献 特開 昭49−102830（ＪＰ，Ａ) 特開 昭58−189110（ＪＰ，Ａ) 特開 昭55−27168（ＪＰ，Ａ) 特開 昭56−122312（ＪＰ，Ａ) 特開 昭57−183716（ＪＰ，Ａ) 薬学領域の高カロリー輸液 平岡栄一著 Ｐ．110〜112（株）医薬ジャーナル社発 行（1980年発行)─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI technical display location // A61K 31/20 ACB 9454-4C (56) References JP-A-49-102830 (JP, A) ) JP-A-58-189110 (JP, A) JP-A-55-27168 (JP, A) JP-A-56-122312 (JP, A) JP-A-57-183716 (JP, A) High calorie in the pharmaceutical area Infusion by Eiichi Hiraoka P. 110-112 Published by Pharmaceutical Journal Co., Ltd. (issued in 1980)
Claims (1)
ミネラルおよびビタミンを主成分とする経管栄養組成物
において、脂質としてリノール酸およびリノレン酸から
選ばれる１種以上の不飽和脂肪酸を５重量％以上含有す
る第１の脂質と、エイコサペンタエン酸およびドコサヘ
キサエン酸から選ばれる１種以上の高度不飽和脂肪酸を
５重量％以上含有する第２の脂質とを、合計量で全固形
分中５〜30重量％配合し、O/W型エマルジョンを形成し
たことを特徴とする経管栄養組成物。1. A carbohydrate, a protein or a degradation product thereof, a lipid,
In a tube-feed nutrition composition containing minerals and vitamins as main components, a first lipid containing 5% by weight or more of one or more unsaturated fatty acids selected from linoleic acid and linolenic acid as lipids, and eicosapentaenoic acid and docosahexaene Forming an O / W emulsion by blending a total amount of 5 to 30% by weight of the total solid content with a second lipid containing 5% by weight or more of one or more highly unsaturated fatty acids selected from acids. A tube-feeding composition characterized by:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59179867A JPH0748991B2 (en) | 1984-08-29 | 1984-08-29 | Tube feeding composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59179867A JPH0748991B2 (en) | 1984-08-29 | 1984-08-29 | Tube feeding composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6158560A JPS6158560A (en) | 1986-03-25 |
| JPH0748991B2 true JPH0748991B2 (en) | 1995-05-31 |
Family
ID=16073295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59179867A Expired - Fee Related JPH0748991B2 (en) | 1984-08-29 | 1984-08-29 | Tube feeding composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0748991B2 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU612149B2 (en) * | 1987-05-01 | 1991-07-04 | Otsuka Pharmaceutical Co., Ltd. | Nutritive emulsion preparation |
| ES2007350A6 (en) * | 1987-05-29 | 1989-06-16 | Ganadera Union Ind Agro | Food products enriched with nucleosides and/or nucleotides and preparation thereof. |
| JP2525624B2 (en) * | 1987-09-21 | 1996-08-21 | 雪印乳業株式会社 | Baby milk powder containing polyunsaturated fatty acids |
| JPH01157364A (en) * | 1987-12-14 | 1989-06-20 | Nippon Oil & Fats Co Ltd | Nutrient composition |
| JP2750721B2 (en) * | 1989-01-31 | 1998-05-13 | 雪印乳業株式会社 | Nutrient composition having an effect of improving serum lipids |
| JPH07102112B2 (en) * | 1990-04-06 | 1995-11-08 | 大塚製薬株式会社 | High protein high viscosity nutritional supplement composition |
| ES2188704T3 (en) * | 1991-04-26 | 2003-07-01 | Mitsubishi Pharma Corp | CONTAINER FILLING WITH INFUSION LIQUIDS. |
| DE69328794T2 (en) * | 1992-10-22 | 2000-11-09 | Yoshitomi Pharmaceutical | CONTAINER WITH TRANSFUSION LIQUID AND PREPARED TRANSFUSION LIQUID |
| US5696463A (en) * | 1993-11-02 | 1997-12-09 | Hyundai Electronics Industries Co., Ltd. | Address transition detecting circuit which generates constant pulse width signal |
| US5728681A (en) * | 1994-04-20 | 1998-03-17 | The Green Cross Corporation | Infusion preparation and two compartment container containing the preparation |
| US5798371A (en) * | 1995-01-13 | 1998-08-25 | Komissarova; Irina Alexeevna | Pharmaceutical composition endowed with an antialcoholic and nootropic effect |
| US5817351A (en) * | 1995-04-07 | 1998-10-06 | Abbott Laboratories | Calcium fortified low pH beverage |
| JPH11503023A (en) * | 1995-04-07 | 1999-03-23 | アボット・ラボラトリーズ | Calcium supplement containing vitamin D and beverage containing calcium |
| EP1275369A1 (en) * | 2001-07-10 | 2003-01-15 | Goldschmidt AG | Folic acid containing personal care product |
| NL1019368C2 (en) * | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparation for improving receptor performance. |
| EP2309879B1 (en) * | 2008-07-15 | 2016-03-30 | Comstock, Robert Lawrence | Improved emulsifying system for nutraceutical composition |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5388245A (en) * | 1977-01-12 | 1978-08-03 | Hitachi Heating Appliance Co Ltd | High frequency heating device |
| AU527784B2 (en) * | 1978-05-26 | 1983-03-24 | Bang, Hans Olaf Dr. | Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid |
| ZA784083B (en) * | 1978-05-26 | 1980-02-27 | Wellcome Found | Fatty acid and derivatives thereof,and formulations containing them for use in treatment or prophyllaxis of thrombo-embolic conditions |
| JPS602162A (en) * | 1983-06-17 | 1985-01-08 | Sanyuu Shoji Kk | Preparation of nutrient food |
| JPS60132916A (en) * | 1983-12-21 | 1985-07-16 | Nisshin Oil Mills Ltd:The | Food or drug for preventing thrombosis |
| JPH0615469B2 (en) * | 1984-05-09 | 1994-03-02 | テルモ株式会社 | Fat infusion |
| JP2574988B2 (en) * | 1993-08-05 | 1997-01-22 | 鹿島建設株式会社 | Reinforcement structure of shield segment joint end |
-
1984
- 1984-08-29 JP JP59179867A patent/JPH0748991B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 薬学領域の高カロリー輸液平岡栄一著Ｐ．１１０〜１１２（株）医薬ジャーナル社発行（１９８０年発行） |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6158560A (en) | 1986-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5860704B2 (en) | Fish oil type parenteral nutrition emulsion fortified with omega-3 in water | |
| JPH0748991B2 (en) | Tube feeding composition | |
| ES2202454T3 (en) | USE OF A BALANCING AGENT FOR OMEGA-3 AND OMEGA-6 Unsaturated FATTY ACIDS. | |
| KR100861889B1 (en) | Supplement to be enterally administered for parenteral nutrition or partial enteral/oral nutrition of the critically ill, the chronically ill and people with malnutrition | |
| DK173068B1 (en) | Lithium-containing pharmaceutical preparations | |
| JPH11508282A (en) | Methods for preventing and treating cachexia and anorexia | |
| EP0127677B1 (en) | Readily-absorpable fatty acid emulsions | |
| ES2674430T3 (en) | Nutritional product to improve tolerance, digestion and absorption of fat soluble nutrients in an infant, toddler or child | |
| WO2006019140A1 (en) | Jelly composition | |
| TWI321989B (en) | Water-soluble composition containing coenzyme q10 | |
| TWI587794B (en) | Formulations and methods for nutrient delivery | |
| WO2006024237A1 (en) | Self emulsifying compositions for delivering lipophilic coenzyme q10 and other dietary ingredients | |
| JPS5924132B2 (en) | Manufacturing method for nutritional supplement emulsion | |
| JP3833648B2 (en) | Water-soluble composition containing coenzyme Q10 | |
| Deitel et al. | Total nutrition by peripheral vein—the lipid system | |
| KR101672347B1 (en) | Infusion preparation | |
| JP2002180082A (en) | Intake material | |
| EP3099289B1 (en) | Composition comprising epa and dha triglycerides for parenteral administration | |
| JPH04152861A (en) | Nutrient composition for nutrition | |
| JP4394174B2 (en) | Inflammatory bowel disease treatment | |
| Schutzman et al. | Neonatal nutrition: a brief review | |
| JP4518042B2 (en) | Method for producing water-soluble composition containing coenzyme Q10 | |
| EP0126666A1 (en) | Compositions used in dietetics, reanimation and therapeutics, containing a protein fraction based on 3 types of minipeptides, and their applications | |
| JP3981991B2 (en) | Aqueous emulsified nutritional composition and use thereof | |
| JP3724740B2 (en) | Tube enteral nutrition containing coenzyme Q10 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |